. . . "Intravenous LD₅₀ in mouse, rat, and rabbit is 340 mg/kg, 520 mg/kg, and 600 mg/kg, respectively. Subcutaneous LD₅₀ in mouse and rat is 1600 mg/kg and >1000 mg/kg, respectively. Oral LD₅₀ in mouse and rat is >3000 mg/kg and >1000 mg/kg, respectively. Nephrotoxicity, ototoxicity and retinal toxicity have been reported following long-term administration for chronic iron overload."@en . . "Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. [PubChem]"@en . . . . . . . "Deferoxamine"@en . . . . . "Deferoxamine mesylate is metabolized principally by plasma enzymes, but the pathways have not yet been defined. Some is also excreted in the feces via the bile."@en . "Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours."@en . . . "D\u00E9feroxamine"@en . "Desferrioxamine"@en . . . "Deferoxamin"@en . . . . "Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum."@en . " "@en . . . . . . . . "Deferrioxamine b"@en . . "DFOA"@en . "Deferoxaminum"@en . "Deferoxamina"@en . "Humans and other mammals"@en . "DFO"@en . "Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions."@en . "Deferrioxamine"@en . . . . . " "@en . . . . . "# \"Link\":http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/203185.html"@en . "Less than 10% bound to serum proteins in vitro."@en . . "70-51-9"@en . . "DFOM"@en . . . . "approved"@en . . . . . . . . . "investigational"@en . . . . "Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa."@en . . . . . . . "Zoltan Konyari, Vilmos Keri, Antal Kovacs, Sandor Horkay, Laszlo Eszenyi, Janos Erdelyi, Ilona Himesi, Gyorgy Toth, Janos Balint, SzilaJudit, Ferenc Vinczi, Csaba Szabo, Nelli Sas, \"Process for the preparation of high-purity deferoxamine salts.\" U.S. Patent US5374771, issued July, 1965."@en . . . . . . . . . . . . . .